Integrated precision dosing for scalable transdermal drug delivery
| Reference number | |
| Coordinator | Flexpenser AB |
| Funding from Vinnova | SEK 184 000 |
| Project duration | October 2025 - June 2026 |
| Status | Ongoing |
| Venture | Medtech4Health: Competence Enhancement in SME |
| Call | Medtech4Health: Competence Enhancement in Small Businesses 2025 |
Purpose and goal
Flexpenser develops sustainable dispensing solutions that reduce waste and protect liquid integrity. Patents granted in the EU, USA, and Canada cover our proprietary one-way valve and precision dosing tech, enabling air-tight, contamination-free dispensing, without preservatives or single-use packaging. We’ve shown proof of concept stability and dosing precision in non-medical applications. This project advances the system toward medical feasibility, focusing on precision dosing patches.
Expected effects and result
Flexpenser’s valve technology has already demonstrated stability and dosing precision in non-medical use, providing proof-of-concept for medical adaptation. This project advances the system to medical feasibility, producing a Target Product Profile, user-informed iteration protocols, and alignment with regulatory and funding pathways. By its conclusion, Flexpenser will be ready to engage global medtech partners, investors, and competitive innovation programs.
Planned approach and implementation
The project includes market analysis, FTO and patent assessment, and technical development with prototyping and user testing. Work is divided into phases with clear milestones and an iterative focus on medical application.